AKT1 and breast carcinoma: Because the PI3K/AKT pathway is involved in resistance to endocrine therapy, HER2-directed therapy, and cytotoxic therapy in breast cancer, the development of inhibitors targeting the PI3K/AKT pathway is very important, and these inhibitors are currently under development or in clinical trials [9,10].